Fujisawa Pharmaceutical Company, Ltd.

Hiroshi Kayakiri

Teruo Kyoto Oku

Yoshito Abe

Yuki Sawada

Hirokazu Tanaka

Shigeki Satoh

Masashi Hashimoto

Takayuki Inoue

Noritsugu Yamasaki

Hitoshi Sawada

Takafumi Imoto

Takahiro Hiramura

Tsuyoshi Mizutani

Hitoshi Hamashima

Yoshio Kawai

Hiroyuki Setoi

Kazuyoshi Kuratani

Masahiro Nishikawa

Katsuya Nakamura

Osamu Onomura

Eishiro Todo

Chiyoshi Kasahara

Akio Kuroda

Naoki Ishibashi

Yuki Saitoh

Noriko Oku

Masayoshi Murata

Hidekazu Takeno

Masanori Okamoto

Kiyoshi Taniguchi

Naoaki Fujii

Akira Kagayama

Minoru Sakurai

Yuji Tokunaga

Yoshiko Yokota

Yasuyo Tomishima

Satoru Kuroda

Hiroaki Ohtake

Tomohiro Oku

Masashi Imanishi

Kenichi Washizuka

Tsutomu Kaizu

Toshio Hattori

Kiyoshi Takatsuki

Miho Kawauchi

Yoshihiro Yokota

Akira Katayama

Chikako Oku, Legal Representative

Tomohito Oku, Legal Representative

Yohsuke Maeda

Chikaka Oku

Takayuji Inoue

Chikako Oku

Tomohito Oku

Tomoaki Iwasa

Yutaka Nakajima

Noriko Oku, Legal Representative

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

Imidazole compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R&#x2014;SONHCO&#x2014;A&#x2014;X&#x2014;R&#x2003;&#x2003;(I)wherein Ris alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and Ris optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Sulfonamide compounds and pharmaceutical use thereof

The present invention relates to a sulfonamide compound of the formula (I):wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

Sulfonamide compounds and uses thereof as medicines

The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof:wherein Rrepresents a lower alkyl group or a lower alkyloxy-lower alkyl group; Rrepresents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; Rrepresents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.

Benzimidazole derivatives

The present invention relates to a compound formula (I) wherein X is bond or &mdash;O&mdash;CH &mdash;, (II) or (III) R is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s), and B is hydrogen; halogen; lower alkyl; lower alkoxycarbonyl; cyclo(lower)alkyl; or a heterocyclic group, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl or phenyl, each of which may be substituted with one or two substituent(s), or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiures or urinary incontinence.

Aminoalcohol derivatives

Sulfonamide compounds and medicinal use thereof

Heterocyclic compounds as bradykinin antagonists

Novel aromatic ring derivatives represented by formula (I) or their pharmaceutical acceptable salts are provided.

Aromatic ring derivatives

This invention relates to a heterocyclic compound of the formula

Benzimidazole compounds as bradykinin antagonists

The invention relates to a pharmaceutical composition for ophthalmic administration comprising a compound of the formula:

Bradykinin antagonist quinolines

This invention relates to compounds of formula: ##STR1## wherein R.sup.6, R.sup.7, R.sup.2, R.sup.2, R.sup.3 and A.sup.1 are as defined in the disclosure; and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

Benzimidazole derivatives as bradykinin agonists

This invention relates to a compound of the formula: ##STR1## wherein A.sup.1 is lower alkylene,

Growing community of inventors

Tsukuba, Japan

Hiroshi Kayakiri